Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation

Liver Transplantation and Surgery

Volumn 4, Issue 5, 1998, Pages 404-409

  Reeves, H L ^a   Francis, R M ^a   Manas, D M ^a   Hudson, M ^a   Day, C P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERALIZATION; DIAGNOSTIC APPROACH ROUTE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT; SPINE FRACTURE;

EID: 0031660229     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500040508     Document Type: Article

References (24)

1. 1 Loeper M, Lemaire A, Lesobre R. Spondylamalacie dans la cirrhose bilaire. Arch Mal App Dig Mal Nutr 1939 ; 29: 577–587.
2. 2 Long RG, Meihard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical biochemical and histological studies of osteomalacia, osteoporosis and parathyroid function in chronic liver disease. Gut 1978 ; 19: 85–90. MEDLINE
3. 3 Matloff DS, Kaplan MM, Neer RM, Goldberg MHJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: Effects of 25‐hydroxyvitamin D 3 treatment. Gastroenterology 1981 ; 83: 97–102.
4. 4 Stellon AJ, Webb A, Compston J, Williams R. Lack of osteomalacia in chronic cholestatic liver disease. Bone 1986 ; 7: 181–195. MEDLINE
5. 5 Meys E, Fontanges E, Fourcade N, Thomasson A, Poyyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am J Med 1994 ; 97: 445–450. MEDLINE
6. 6 Hay JE. Bone disease in liver transplant recipients. Gastroenterol Clin North Am 1993 ; 22: 337–349. MEDLINE
7. 7 McDonald JA, Dunstan CR, Dilworth P, Sherborn K, Sheil AGR, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology 1991 ; 14: 613–619. MEDLINE
8. 8 Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991 ; 14: 296–300. MEDLINE
9. 9 MacIntyre I, Whitehead MI, Banks LM, Stevenson JC, Wimalawansa SJ, Healy MJR. Calcitonin for prevention of postmenopausal bone loss. Lancet 1998 ; 1: 900–901.
10. 10 Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study. Thorax 1994 ; 49: 1099–1102. MEDLINE
11. 11 Momtemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid‐induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991 ; 49: 71–76. MEDLINE
12. 12 Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliry cirrhosis. Hepatology 1994 ; 20: 633–637. MEDLINE
13. 13 Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994 ; 79: 1595–1599. MEDLINE
14. 14 Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996 ; 23: 1560–1564. MEDLINE
15. 15 Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995 ; 333: 1437–1443. MEDLINE
16. 16 Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. for the Fracture International Trial Research Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996 ; 348: 1535–1541. MEDLINE
17. 17 Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid‐induced osteoporosis. Am J Med 1995 ; 99: 235–242. MEDLINE
18. 18 Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, et al. Intermittent cyclical therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994 ; 21: 1922–1926. MEDLINE
19. 19 Reid IR, King AR, Alexznder CJ, Ibbertson HK. Prevention of steroid induced osteoporosis with (3‐amino‐1‐hydroxypylidine)‐l,l‐bisphosphonate (APD). Lancet 1988 ; 1: 143–146. MEDLINE
20. 20 Wolfhagen FHJ, van Buuren HR, den Ouden JW, Hop WCJ, van Leeuwen JPTM, Schalm SW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‐treated primary biliary cirrhosis. J Hepatol 1997 ; 26: 325–330. MEDLINE
21. 21 Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, et al. Intermittent treatment with intravenous 40amino‐1‐hydroxybutylidene‐1,1‐bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991 ; 15: 237–247. MEDLINE
22. 22 Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 1993 ; 95 (suppl 5A): 48S–52S. MEDLINE
23. 23 Cooper C, Melton LJ. Vertebral fractures. BMJ 1992 ; 304: 793–794. MEDLINE
24. 24 Ettinger B, Black DM, Nevitt MC, Rundle AC, Caley JA, Cummings SR, et al. Contribution of vertebral deformities to chronic back pain and disability. The study of osteoporotic fractures research group. J Bone Miner Res 1992 ; 7: 449–456. MEDLINE